scholarly journals Early Occurrence of Two Distinct Histological Types of Renal Cell Carcinoma in End-Stage Renal Disease Patient on Haemodialysis

2020 ◽  
Vol 7 (12) ◽  
pp. C183-187
Author(s):  
Mayur Parkhi ◽  
Aravind Sekar ◽  
Kalpesh Parmar ◽  
Shubajit Mandal

Background:  The occurrence of renal cell carcinoma is a well-known complication in end-stage renal disease on haemodialysis. Various histological types of renal cell carcinomas are observed in these patients and varies with the duration of haemodialysis. Though the synchronous association of two renal cell carcinomas in the patients are known, the existence of such dual renal tumours in the patient on dialysis is extremely rare and unheard in the English literature. Moreover, tubulocystic renal cell carcinoma is rarely reported in this setting. Case report and Discussion: We describe an unusual early synchronous occurrence of two tumours with distinct histology i.e. Papillary renal cell carcinoma (PRCC, type I) and Tubulocystic renal cell carcinoma (TC-RCC) in a patient with end-stage renal disease on haemodialysis for a duration less than a year. Though exact etiological factors peculiar to the occurrence of these tumours are not known, increased oxidative stress occurring in end-stage renal disease patient on haemodialysis might play an important role in carcinogenesis. Conclusion: Renal cell carcinoma with more than one histological type may occur exceedingly early without any symptoms in these patients. Radiologists and urologists should be aware of it for early diagnosis and prompt treatment. Pathologists should also be more cautious while grossing and pick the sub-centimetric primary or secondary tumours that may have an impact on patient survival.

2010 ◽  
Vol 105 (5) ◽  
pp. 620-627 ◽  
Author(s):  
Mohammed A.A.M. Nouh ◽  
Naoto Kuroda ◽  
Motoki Yamashita ◽  
Yushi Hayashida ◽  
Toshifumi Yano ◽  
...  

Cases Journal ◽  
2009 ◽  
Vol 2 (1) ◽  
Author(s):  
Christoforos Kosmıdis ◽  
Christoforos Efthimiadis ◽  
Georgios Anthimidis ◽  
Marios Grigoriou ◽  
Kalliopi Vasiliadou ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-4 ◽  
Author(s):  
Jawaher Ansari ◽  
Muhammad Ali ◽  
Ashraf Farrag ◽  
Arwa M. Ali ◽  
Abdulaziz Alhamad

Treatment of patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD) on dialysis poses a therapeutic challenge, particularly as this patient group was excluded from the pivotal clinical trials. In addition, there is uncertainty regarding drug dosing/pharmacokinetics, lack of safety and efficacy data, and potential for increased toxicity when using targeted therapy or immunotherapy for the management of patients with mRCC on dialysis. Nivolumab, an anti-programmed death-1 immune checkpoint inhibitor antibody, is indicated for the treatment of patients with mRCC who have received prior antiangiogenic therapy. Given the above-mentioned uncertainties, clinicians may be reluctant to use nivolumab for this patient population, leading to potential denial of life-prolonging medications. We report the case of a 72-year-old gentleman with mRCC and ESRD on dialysis who received second-line nivolumab therapy and achieved an excellent symptomatic and radiological response, remaining progression-free for over 22 months. In addition, we have reviewed the pharmacokinetic data and published retrospective case studies to review the management options for patients with mRCC and ESRD on dialysis.


10.5772/59378 ◽  
2015 ◽  
Author(s):  
Yasukazu Nakanishi ◽  
Fumitaka Koga ◽  
Hiroshi Fukushima ◽  
Toru Motoi ◽  
Ken-ichi Tobisu

Sign in / Sign up

Export Citation Format

Share Document